In this application note, we describe a streamlined disulfide bond mapping analysis workflow using the Waters Biopharmaceutical Platform Solution with UNIFI. An innovator biologic, infliximab, is compared with a biosimilar.
This application note demonstrates successful application of the described workflow to identify all expected disulfide bonds from the Waters mass check standards. Additionally, it demonstrated the comparability between innovator and biosimilar infliximab samples.
Combined with the UNIFI compliance-ready architecture, this disulfide mapping workflow can help biopharmaceutical organizations overcome analytical challenges, and complete fast mapping and monitoring of disulfide bonds during the development and manufacturing of their biotherapeutic products.